In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has been given a consensus rating of “Reduce” by the ten brokerages that are covering the stock, Ratings reports. One equities research analyst ...

The National Vector Borne Disease Control Programme (NVBDCP), under the Department of Health & Family Welfare, Government of ...

Share on Pinterest Scientists have found that an antibody treatment prevented a decline in muscle mass and bone density after using GLP-1 drugs. Rob and Julia Campbell/Stocksy Aging and limited ...

Anti-C1q antibodies were present among 74.3% of patients with immunoglobulin G4-related disease. Anti-C1q antibodies are highly prevalent among patients with immunoglobulin G4-related disease (IgG4-RD ...

However, the strength of the evidence is incomplete due to insufficient validation of the monoclonal antibodies used to deplete IgM, which limits confidence in the main claims. Addressing these ...

Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory ...

An ANA blood test (antinuclear antibody test) is usually performed on a blood sample as part of the diagnostic process for certain autoimmune diseases. It is usually ordered along with other blood ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...